Tetrapeptide Inhibits Atopic Dermatitis via Mast Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atopic dermatitis, such as steroids and antihistamines, have significant side effects and are not effective in the long term, and existing peptide-based treatments are not fully curative, highlighting the need for a more effective and safer option to inhibit skin inflammation.
Innovation Solution
A peptide with the amino acid sequence Arg-Leu-Tyr-Glu, potentially acetylated and linked with a cell-penetrating peptide, is developed to inhibit atopic dermatitis by reducing IgE and histamine levels and restoring tight junction-related proteins, offering a pharmaceutical composition for prevention and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroids are used to treat skin inflammation, then anti-inflammatory effect is improved, but side effects increase
Solution Approach 1:
The patent uses a tetrapeptide (ARG-LEU-TYR-GLU) as a temporary, non-systemic treatment that acts locally on mast cells and resolves inflammation without the long-term side effects of steroids. The peptide is administered repeatedly at low doses, providing sustained relief without cumulative harm.
Solution Approach 2:
The patent changes the molecular structure and mechanism of action by using a specific tetrapeptide sequence that targets mast cell degranulation. This parameter change in the active ingredient's structure enables anti-inflammatory effect without the harmful side effects of conventional steroids.
2Reliability
If antihistamines are used to treat skin inflammation, then histamine release is inhibited, but effectiveness in long-term use decreases
Solution Approach 1:
The patent extracts and targets the specific mechanism of mast cell degranulation and histamine release through a tetrapeptide that directly inhibits this process. By focusing on this specific pathway rather than general histamine blocking, the treatment achieves sustained effectiveness.
Solution Approach 2:
The tetrapeptide treatment provides continuous inhibition of mast cell degranulation through repeated applications. The peptide maintains its activity over time, ensuring continuous suppression of inflammatory mediators without the diminishing effectiveness associated with antihistamines.
3Reliability
If synthetic drugs like chromoglycic acid and tranilast are used, then mast cell mediator release is inhibited, but complete cure is not achieved and systemic side effects occur
Solution Approach 1:
The tetrapeptide ARG-LEU-TYR-GLU exhibits local action by binding specifically to mast cells in the skin, inhibiting degranulation at the site of inflammation. This localized mechanism avoids the systemic distribution and side effects associated with synthetic drugs like chromoglycic acid and tranilast.
Solution Approach 2:
The patent uses a natural peptide sequence (ARG-LEU-TYR-GLU) that mimics biological signaling molecules, allowing it to interact with mast cell receptors in a manner that is both effective and biocompatible. This natural copying approach avoids the harsh side effects of synthetic analogs.
4Reliability
If higher doses of peptide are used to achieve better therapeutic effect, then anti-atopic effect increases, but cost and complexity increase
Solution Approach 1:
The patent applies partial action by using low doses of the tetrapeptide that are sufficient to achieve therapeutic effect. The peptide's high specificity for mast cells means that even small amounts provide effective inhibition, avoiding the need for high doses that would increase cost and complexity.
Solution Approach 2:
The patent optimizes the peptide sequence (ARG-LEU-TYR-GLU) to achieve maximum binding affinity and activity at low concentrations. This parameter optimization in the peptide structure allows therapeutic effect at minimal doses, reducing overall treatment complexity.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a peptide for inhibiting skin inflammation and a pharmaceutical composition and a cosmetic composition for preventing or treating skin inflammation including the same. Since the peptide, pharmaceutical composition and cosmetic composition are effective for improving symptoms of skin inflammation caused by atopic dermatitis and the like, they are useful for preventing, improving or treating skin inflammation.